Streetbeat News

Stock Prices

SYF

Synchrony Financial reported a strong Q3 with a 29% profit growth, beating earnings expectations. The company raised its FY24 EPS forecast and saw a 4.90% premarket share price increase.

Portfolio Pulse from Akanksha Bakshi

October 16, 2024 | 11:44 am

GM

LAC

Lithium Americas shares rise following a new investment agreement with General Motors to create a joint venture for the Thacker Pass project in Nevada.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:36 am

BA

EADSY

Boeing faces a prolonged strike by its workers demanding better wages and pensions, while Airbus plans to cut 2,500 jobs in its Defence & Space division due to financial setbacks. The aerospace industry is under pressure despite strong stock performance.

Portfolio Pulse from Pooja Rajkumari

October 16, 2024 | 11:35 am

ABT

Abbott Laboratories has projected its Q4 2024 adjusted earnings per share (EPS) to be between $1.31 and $1.37, surpassing the consensus estimate of $1.20.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:35 am

ABT

Abbott has updated its full-year 2024 adjusted EPS guidance to a range of $4.64 to $4.70, slightly narrowing its previous range of $4.61 to $4.71. This new guidance aligns closely with the consensus estimate of $4.66.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:34 am

MS

Morgan Stanley reported Q3 2024 earnings of $1.88 per share, surpassing the analyst estimate of $1.58. Sales reached $15.38 billion, exceeding the expected $14.41 billion and marking a 15.90% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:31 am

ALZN

Alzamend Neuro (NASDAQ:ALZN) has released the full data set from its Phase 2A trial for AL001, a treatment for dementia related to Alzheimer's. The study found the treatment to be safe and well-tolerated, paving the way for further clinical trials. Alzamend plans to conduct five additional trials to compare lithium levels in the brain with those from a marketed lithium salt.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 11:30 am

ALZN

Alzamend Neuro has confirmed positive topline results from June 2023, identifying a maximum tolerated dose as assessed by an independent safety review committee.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:30 am

ALZN

Alzamend Neuro has announced the full data set for its Phase IIA clinical trial of AL001, a treatment for dementia related to Alzheimer's. This development is a significant step in the company's research efforts.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:30 am

SYF

Synchrony Financial shares rose after the company reported better-than-expected Q3 results and increased its FY24 EPS guidance.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 11:29 am